Case Reports in Endocrinology
Volume 2015 (2015), Article ID 252157, 7 pages
http://dx.doi.org/10.1155/2015/252157

Case Report

Thyroid Carcinoma with Pituitary Metastases: 2 Case Reports and Literature Review

Weiying Lim, Dawn Shaoting Lim, Chiaw Ling Chng, and Adoree Yiying Lim

Singapore General Hospital, Outram Road Singapore 169608

Received 1 December 2014; Accepted 31 December 2014

Academic Editor: Wayne V. Moore

Copyright © 2015 Weiying Lim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

We present 2 patients with pituitary metastases from thyroid carcinoma—the first from anaplastic thyroid carcinoma and the second from follicular thyroid carcinoma. The first patient, a 50-year-old lady, presented with 2-week history of hoarseness of voice, dysphagia, dyspnoea, and neck swelling. Imaging revealed metastatic thyroid cancer to lymph nodes and bone. Histology from surgery confirmed anaplastic thyroid cancer. She was found to have pituitary metastases postoperatively when she presented with nonvertiginous dizziness. She subsequently underwent radiotherapy and radioiodine treatment but passed away from complications. The second patient, a 65-year-old lady, presented with loss of appetite and weight with increased goitre size and dyspnoea. Surgery was performed in view of compressive symptoms and histology confirmed follicular thyroid carcinoma. Imaging revealed metastases to bone, lung, and pituitary. She also had panhypopituitarism with hyperprolactinemia and diabetes insipidus. She received radioiodine therapy but eventually passed away from complications.

1. Introduction

Pituitary metastases are rare. They are found in only 1% of all pituitary resections and only 2% of these are from thyroid carcinoma [1]. We report two unusual cases of anaplastic and follicular thyroid cancers who presented with pituitary metastases. A literature review of these rare metastases and the challenges encountered in the management of the pituitary metastases in these cases were also highlighted in this report [1, 2].

2. Case Presentation

2.1. Case 1

A 50-year-old woman presented with a 2-week history of progressive neck swelling, hoarseness of voice, dyspnoea, and dysphagia. Systemic review was otherwise unremarkable. Physical examination revealed a hard thyroid mass extending from the thyroid cartilage to just above the supraclavicular notch. Initial fine needle aspiration cytology (FNAC) of the thyroid, done at another institution, was suspicious for Hurtle cell carcinoma.

Three months later, she sought a second opinion at our institution. Computed tomography (CT) and F-18-FDG-positron emission tomography (PET) whole body scans (from skull vertex to upper thighs) were done to evaluate the extent of disease and revealed aggressive thyroid carcinoma with metastases to the manubrium and left cervical levels II–IV and supraclavicular lymph nodes (Figures 1(a)–1(c)). She underwent a total thyroidectomy, laryngectomy with bilateral neck dissection 3 weeks later. Histology revealed poorly differentiated thyroid carcinoma of TNM stage T4N1M1. The tumor measured with large area of central necrosis and extrathyroidal extension to the perithyroidal soft tissue and laryngeal cartilage. 78 cervical lymph nodes were examined and 8 were involved (10%). BRAF mutation was negative.

(a)

(b)

(c)

Figure 1: PET-CT scan showing (a) hypermetabolic enlarged thyroid gland, (b) hypermetabolic left cervical lymph node, and (c) hypermetabolic focus in right side of manubrium (indicated by arrows).

She was discharged but readmitted 26 days after surgery with nonvertiginous dizziness. Magnetic resonance imaging (MRI) of the brain showed enhancing tissue in the left cavernous sinus, left V3 branch of trigeminal nerve, and left sphenoid sinus. There was also involvement of the pituitary gland and erosion of the left lateral aspect of sellar floor. Hormonal profile showed normal pituitary function and no evidence of diabetes insipidus. She was scheduled for 10 fractions of 30 Gy palliative radiotherapy to the base of skull and cavernous sinus metastasis. Her postoperative thyroglobulin level was 704 UG/L (2–70 UG/L), with negative thyroglobulin antibodies.

However, she developed left ptosis and diplopia while undergoing radiotherapy. Physical examination revealed left complete ptosis and incomplete left eye adduction. Repeat MRI imaging of the pituitary gland showed enlargement of the pituitary gland with mildly thickened infundibular stalk and a stable left cavernous sinus mass measuring with encasement of the cavernous portion of the left internal carotid artery (Figures 2(a) and 2(b)).

(a)

(b)

Figure 2: MRI brain (T2-weighted, contrast, and coronal) showing (a) pituitary involvement and (b) invasion into left cavernous sinus (indicated by arrows).

She completed the full course of radiotherapy and was also given a single ablative dose of radioactive iodine at 200 mci. The pituitary metastasis was non-iodine-avid. Unfortunately, she showed no improvement in her clinical condition and passed away a few months later.

2.2. Case 2

A 65-year-old woman presented with loss of appetite and weight, increased goitre size, and increased dyspnoea. Systemic review was unremarkable. Physical examination revealed a nodular goitre with retrosternal extension with no associated cervical lymphadenopathy.

CT scan revealed a large L4 vertebral body lytic lesion and an 8 mm pulmonary nodule in the left lung base, suspicious for metastases. She underwent a CT-guided biopsy of the L4 vertebral body lytic lesion which revealed the presence of tumour cells which stained positive for CK7, TTF-1, and thyroglobulin. These findings suggested possible primary pulmonary or thyroid malignancy. FNAC of the thyroid, however, revealed benign follicular cells with focal Hurtle cell changes.

CT scan of the neck was performed to evaluate the degree of airway obstruction and, limited views of the brain, incidentally revealed a pituitary mass. There was asymmetric enlargement of the thyroid with heterogeneous enhancement and areas of calcifications. The left thyroid lobe measures while the right thyroid lobe measures . There is mass effect with deviation of the trachea to the right side. At its narrowest point, the trachea measures approximately . No significant cervical lymphadenopathy was noted.

The pituitary mass was further evaluated by MRI imaging. It measured with some haemorrhagic changes and invasion of the left cavernous sinus. Mass effect noted on the optic chiasm on imaging prompted formal ophthalmological examination, which showed right central scotoma with left inferior hemifield defect. Her hormonal profile revealed panhypopituitarism, hyperprolactinemia from “stalk effect,” and diabetes insipidus (Table 1).

Table 1: Baseline laboratory results showing presence of panhypopituitarism, hyperprolactinemia, and diabetes insipidus.

Blood investigations
Result
Normal reference

Random cortisol (10 am)
<11 nmol/L
—

Free thyroxine
3.9 pmol/L
8.8–14.4

Thyroid stimulating hormone
0.846 mu/L
0.65–3.70

Follicle stimulating hormone
1.7 u/L
1.0–14.0

Luteinizing hormone
0.1 u/L
1.0–24.0

Estradiol
38.4 pmol/L
37.0–1284

Prolactin
83.3 u/L
5.0–27.7

Growth hormone
0.3 mu/L
0–28.5

Insulin-like growth factor-1
84.0 ug/L
80–197

Sodium
147 mmo/L
135–145

Osmolality
308 mmol/kg
275–301

Urine osmolality
112 mmol/kg
50–1200

Given the clinical context of an enlarging goitre with relative rapidity, the likelihood of a thyroid malignancy was deemed more probable than pulmonary malignancy. In view of significant obstructive symptoms, she underwent a total thyroidectomy without bilateral neck dissection and histology revealed a diagnosis of follicular thyroid carcinoma with capsular and vascular invasion of T4N0M1 staging. Test for BRAF mutation was not performed. Her postsurgical thyroglobulin was 11710 UG/L (2–70 UG/L) with a corresponding thyroglobulin antibody of 835 U/mL (0–60 U/mL).

She had progressive blurring of vision and a repeat MRI pituitary scan showed a further enlargement of the pituitary mass, with dimensions of and increased mass effect on the optic chiasm with extension into bilateral cavernous sinuses (Figures 3(a) and 3(b)).

(a)

(b)

Figure 3: (a) MRI pituitary (T1-weighted, contrast, and coronal) showing pituitary mass (long arrow) with mass effect on the optic chiasm (short arrow). (b) MRI pituitary (T1-weighted, contrast, and sagittal) showing presence of increased signal intensity in the pituitary mass, representing presence of blood products (long arrow).

She underwent a transsphenoidal resection of the pituitary mass which confirmed the presence of pituitary metastases from the thyroid follicular carcinoma. She subsequently suffered a left femur shaft fracture after a fall requiring internal fixation. Tissue histology from the fracture site revealed thyroid follicular carcinoma. She received 2 doses of radioactive iodine (250 mci each approximately 5 months apart) but unfortunately passed away from intraventricular haemorrhage after the second RAI treatment. The pituitary metastases were iodine-avid and after first RAI thyroglobulin was 27490 UG/L.

3. Discussion

Metastatic tumours can involve the pituitary by means of haematogenous spread, direct invasion from skull base metastasis, or meningeal spread through the suprasellar cistern [3]. Haematogenous spread can occur via the hypophyseal arteries or the portal system. As the posterior lobe of the pituitary is directly exposed to the arterial circulation, metastases to the pituitary gland from other malignancies have a predilection for the posterior lobe. However, pituitary metastases from thyroid carcinomas seem to differ from the norm, with diabetes insipidus affecting only 5 out of 22 of the reported cases (summarised in Table 2). One suggested reason for this phenomenon is that pituitary metastases from thyroid carcinomas tend to be relatively rapid growing parasellar lesions rather than intrasellar lesions that destroy pituitary tissue or interrupt the pituitary stalk [4], hence presenting more often with mass effect.

Table 2: Summary of reported cases (including our 2 cases).

Authors
Year
Cell type*
Pituitary complications
Known thyroid primary
Timing from thyroid primary
RAI if known thyroid primary
Other Rx
Other sites of metastases
Age
Sex
Rx
Outcomes

Johnson and Atkins [8]
1965
P
Visual field defect
CN III, CN IV
Yes
14 years
No
External beam RT
Local recurrence
56
F
Roentgen therapy
Adjuvant RAI
Follow-up

Pelosi et al. [10]
1977
P
Hypopituitarism
Ophthalmoplegia
No
NA
NA
No
No
32
M
Transcranial surgery
Death 1 month after presentation

Sziklas et al. [11]
1985
P
Hypopituitarism
DI
Yes
25 years
No
No
Bone
Chest wall
44
M
Transsphenoidal resection
RAI
Death 13 months after due to massive intrathoracic haemorrhage

Masiukiewicz et al.
(Case  1) [12]
1999
P
Central hypothyroidism Hypogonadism
Hypoadrenalism
Yes
5 years
Yes, at diagnosis and repeated doses for recurrence
Repeated surgical clearance
Repeated local recurrence
Lungs
56
M
No surgery
RAI
Progressive lung and bone metastases

Masiukiewicz et al. (Case  2) [12]
1999
P
CN III deficit
Hypogonadism
Yes
20 years
Yes, several years after diagnosis without clinical response
Radiosurgery
Local recurrence Bone
Lungs
55
F
Stereotactic radiosurgery
Surgical debulking
RAI
Death after 7 months

Bell et al. [13]
2001
P
Visual field defect
DI
Amenorrhea
Yes
25 years
For pulmonary metastases 8 years after thyroidectomy
Neck RT at diagnosis of thyroid cancer
Lung
35
F
Transsphenoidal resection
Follow-up
DI post-op

Barbaro et al. (Case  2) [14]
2013 (2011)
P
Ophthalmoplegia
Yes
2 months
Yes
No
No
65
F
Surgical intervention
EBRT
Follow-up for 2 months

Trunnell and Marinelli [15]
1949
F
Visual field defect
Yes
1 year
No
No
Bone
42
F
2 RAI
Follow-up

Kistler and Pribram [16]
1975
F
Visual field defect
CN III
Yes
9 years
Yes
No
No
69
F
Craniotomy but unresectable
Autopsy confirming thyroid metastases
Death

Ochiai et al. [17]
1992
F
CN III, CN IV
No
NA
NA
NA
No
62
F
Transsphenoidal resection
RAI
Follow-up
Hormonal replacement therapy

Chrisoulidou et al. [18]
2004 (case 1996)
F
CN III
Yes
4 years
Yes
External beam RT
Chemo (paraplatin/vepeside)
No
60
M
Transsphenoidal resection
Follow-up
Hormonal suppressive therapy
Hormonal replacement

Simon et al. [19]
2004
F
CN III, CN IV
Raised ICP
No
NA
NA
NA
No
23
F
Transsphenoidal surgery abandoned RAI
Follow-up

Yilmazlar et al. [20]
2004
F
Visual field defect
Raised ICP
Galactorrhea
Yes
22 months
Yes
No
No
43
F
Transsphenoidal resection
RAI × 3
Hormonal suppressive therapy
Follow-up

Prodam et al. [4]
2010
F
Visual disturbance
Raised ICP
Stalk effect
Transient DI post-op
No
NA
RAI after thyroidectomy after pituitary lesion was found
No
Local lymph nodes
Pelvic mets
45
F
Transsphenoidal surgery
RAI
Follow-up
KIV for 3rd RAI

Vianello et al. [21]
2011 (case 2001)
F
Visual field deficits
Pain to right orbit
Hypopituitarism
No
NA
RAI after thyroidectomy after pituitary lesion was found
External beam RT
Lung
Bone
Soft tissue, muscle
Skull
61
F
Transnasopharyngeal biopsy
Total thyroidectomy
External beam radiotherapy to sellar
RAI × 7
Follow-up for 10 years

Bhatoe et al. [22]
2008 (case 2001)
M
Visual field defect
Stalk effect
Hypogonadism-decreased libido, gynecomastia
No
NA
NA
NA
No
36
M
Craniotomy and subfrontal resection
Adjuvant radiotherapy
Follow-up for 9 months

Santarpia et al. [23]
2009 (2005)
M
Raised intracranial pressure
Visual field deficit
DI
Panhypopituitarism
Yes
15 years
No
No
Local lymph nodes
Bone
Lungs
Liver
23
F
Transsphenoidal resection
Death 2 months after surgery due to intercurrent infection

Williams et al. [24]
2008
M
DI
Visual field deficit
Yes
15 years
No
No
Lung
Bone
Liver
Breast
23
F
Transsphenoidal resection
Follow-up

Bobinski et al. [25]
2009
M
Apoplexy
Hydrocephalus
Large suprasellar mass
No
NA
NA
NA
No
46
F
Craniotomy and tumour debulking
Death

Conway et al. [26]
2012
M
DI
Panhypopituitarism
No
NA
NA
NA
Parotid
Bilateral adrenals
Bone
Cerebellum
61
M
Craniotomy
Palliative radiation to pituitary and combination chemotherapy
Follow-up for 13 months

Case  1
2011
A
CN III
Yes
26 days
Yes
RT
Lymph node
Bone
50
F
RT
RAI
Death

Case  2
2010
F
Panhypopituitarism
DI
Optic neuropathy
No
NA
Yes
NA
Bone
Lungs
65
F
Transsphenoidal surgery
RAI
Death

P: papillary, F: follicular, M: medullary, and A: anaplastic.

From the reported cases, direct invasions from skull base metastasis tend to be associated with large metastasis and are mostly from follicular thyroid carcinoma. In our first case, there was erosion of the sellar floor but it is difficult to ascertain the mode of spread in view of the rapid and aggressive growth of the carcinoma. In our second case, there was selective involvement of the pituitary gland with no evidence of bony involvement or meningeal enhancement; hence haematogenous spread is most likely.

Patients can present with symptoms related to mass effect from parasellar mass enlargement, such as ptosis, blurring of vision, and oculomotor and abducens nerve palsies. Rarer symptoms include diabetes insipidus and hypopituitarism. Our first case presented with oculomotor nerve palsy and preserved pituitary gland function. Our second case presented with panhypopituitarism, diabetes insipidus, and optic neuropathy. In the first case, the initial F-18-FDG-PET/CT scan did not reveal the pituitary metastasis. We postulate two reasons: (i) aggressive cancer (the pituitary metastasis was not present initially but developed quickly over the course of 3 months); (ii) F-18-FDG-PET scan does not pick up pituitary metastasis well [5] (the brain being very metabolically hyperactive would appear FDG-avid and may mask any pituitary metastasis).

One other observation is that, in both our cases, the initial thyroid FNAC returned to be falsely reassuring, likely to be due to “sampling error” from the large thyroid mass [6]. The false negative rate is higher in thyroid nodules larger than 4 cm [7]. In such cases, a thyroid core biopsy could be a better alternative.

The presence of pituitary metastases could be challenging to manage. If the metastases are large and locally invasive, surgical clearance may be difficult. In view of close proximity to the optic chiasm as well as cranial nerves like oculomotor nerve, trochlear nerve, and abducens nerve, external beam radiotherapy and radiosurgery could be difficult to plan. In patients with poorly differentiated thyroid carcinomas, there is typically poor radioiodine uptake which would reduce the efficacy of radioactive iodine therapy. In patients in whom there is radioactive iodine uptake by the thyroid carcinoma cells, there is also a potential risk of pituitary apoplexy or haemorrhage in view of the acute increase in pituitary volume from acute swelling induced by radioactive iodine [8].

Despite aggressive therapy, prognosis for patients who have pituitary metastases from thyroid carcinoma is poor. All the patients reported in the literature passed away except one [9]. In this rare case, the 48-year-old male presented with seizures and visual disturbance and was found to have a pituitary mass. Surgical resection of the pituitary mass was performed which showed metastatic papillary thyroid carcinoma. An ultrasound thyroid was done but was normal. This patient underwent total thyroidectomy and histology showed two small foci of papillary microcarcinoma with the largest measuring 1.5 mm in greatest diameter. This patient was treated with ablative radioactive iodine (200 mci) and has been disease-free since. In contrast, most other cases fare poorer as the thyroid carcinoma foci tend to be larger and more locally advanced. Therefore, early diagnosis and collaborative management with neurosurgeons, radiation oncologists, nuclear medicine physicians, and endocrinologists is important for treatment of such patients.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

J. Komninos, V. Vlassopoulou, D. Protopapa et al., “Tumors metastatic to the pituitary gland: case report and literature review,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 574–580, 2004.

D. R. Fassett and W. T. Couldwell, “Metastases to the pituitary gland,” Neurosurg Focus, vol. 16, no. 4, p. E8, 2004.

S. S. Chhiber, A. R. Bhat, S. H. Khan et al., “Apoplexy in sellar metastasis: a case report and review of literature,” Turkish Neurosurgery, vol. 21, no. 2, pp. 230–234, 2011.

F. Prodam, L. Pagano, S. Belcastro et al., “Pituitary metastases from follicular thyroid carcinoma,” Thyroid, vol. 20, no. 7, pp. 823–830, 2010.

S. H. Hyun, J. Y. Choi, K.-H. Lee, Y. S. Choe, and B.-T. Kim, “Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria,” Journal of Nuclear Medicine, vol. 52, no. 4, pp. 547–550, 2011.

Y. Y. Tee, A. J. Lowe, C. A. Brand, and R. T. Judson, “Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review,” Annals of Surgery, vol. 246, no. 5, pp. 714–720, 2007.

K. L. McCoy, N. Jabbour, J. B. Ogilvie, N. P. Ohori, S. E. Carty, and J. H. Yim, “The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size,” Surgery, vol. 142, no. 6, pp. 837.e3–844.e3, 2007.

P. M. Johnson and H. L. Atkins, “Functioning metastasis of thyroid carcinoma in the sella turcica,” The Journal of Clinical Endocrinology and Metabolism, vol. 25, pp. 1126–1130, 1965.

J. D. Simmons, T. W. Pinson, K. A. Donnellan, C. F. Harbarger, K. T. Pitman, and R. Griswold, “A rare case of a 1.5 mm papillary microcarcinoma of the thyroid presenting with pituitary metastasis,” American Surgeon, vol. 76, no. 3, pp. 336–338, 2010.

R. M. Pelosi, J. H. Romaldini, L. T. Massuda, L. C. Reis, and L. C. França, “Pan-hypopituitarism caused by to sellar metastasis from papilliferous carcinoma of the thyroid gland associated with secondary thrombophlebitis of the cavernous sinus and purulent leptomeningitis,” AMB: Revista da Associação Médica Brasileira, vol. 23, no. 8, pp. 277–280, 1977.

J. J. Sziklas, J. Mathews, R. P. Spencer, R. J. Rosenberg, M. T. Ergin, and B. F. Bower, “Thyroid carcinoma metastatic to pituitary,” Journal of Nuclear Medicine, vol. 26, no. 9, p. 1097, 1985.

U. S. Masiukiewicz, I. A. Nakchbandi, A. F. Stewart, and S. E. Inzucchi, “Papillary thyroid carcinoma metastatic to the pituitary gland,” Thyroid, vol. 9, no. 10, pp. 1023–1027, 1999.

C. D. Bell, K. Kovacs, E. Horvath, H. Smythe, and S. Asa, “Papillary carcinoma of thyroid metastatic to the pituitary gland,” Archives of Pathology and Laboratory Medicine, vol. 125, no. 7, pp. 935–938, 2001.

D. Barbaro, N. Desogus, and G. Boni, “Pituitary metastasis of thyroid cancer,” Endocrine, vol. 43, no. 3, pp. 485–493, 2013.

J. B. Trunnell and L. D. Marinelli, “The treatment of metastatic thyroid cancer with radioactive iodine; credits and debits,” The Journal of Clinical Endocrinology & Metabolism, vol. 9, no. 11, pp. 1138–1152, 1949.

M. Kistler and H. W. Pribram, “Metastatic disease of the sella turcica,” The American Journal of Roentgenology, Radium Therapy and Nuclear Medicine, vol. 123, no. 1, pp. 13–21, 1975.

H. Ochiai, S. Nakano, T. Goya, S. Wakisaka, and K. Kinoshita, “Pituitary metastasis of thyroid follicular adenocarcinoma. Case report,” Neurologia Medico-Chirurgica, vol. 32, no. 11, pp. 851–853, 1992.

A. Chrisoulidou, K. Pazaitou-Panayiotou, N. Flaris et al., “Pituitary metastasis of follicular thyroid carcinoma,” Hormone Research, vol. 61, no. 4, pp. 190–192, 2004.

N. Simon, S. A. Quyyumi, and J. G. Rothman, “Follicular thyroid cancer presenting as a sellar mass: case report and review of the literature,” Endocrine Practice, vol. 10, no. 1, pp. 62–66, 2004.

S. Yilmazlar, H. Kocaeli, and T. Cordan, “Sella turcica metastasis from follicular carcinoma of thyroid,” Neurological Research, vol. 26, no. 1, pp. 74–78, 2004.

F. Vianello, R. Mazzarotto, A. Taccaliti et al., “Follicular thyroid carcinoma with metastases to the pituitary causing pituitary insufficiency,” Thyroid, vol. 21, no. 8, pp. 921–925, 2011.

H. S. Bhatoe, S. Badwal, V. Dutta, and N. Kannan, “Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature,” Journal of Neuro-Oncology, vol. 89, no. 1, pp. 63–67, 2008.

L. Santarpia, R. F. Gagel, S. I. Sherman, N. J. Sarlis, D. B. Evans, and A. O. Hoff, “Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer,” Head & Neck, vol. 31, no. 3, pp. 419–423, 2009.

M. D. Williams, S. L. Asa, and G. N. Fuller, “Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis,” Annals of Diagnostic Pathology, vol. 12, no. 3, pp. 199–203, 2008.

M. Bobinski, C. M. Greco, and R. J. Schrot, “Giant intracranial medullary thyroid carcinoma metastasis presenting as apoplexy,” Skull Base, vol. 19, no. 5, pp. 359–362, 2009.

A. Conway, A. Wiernik, A. Rawal, C. Lam, and H. Mesa, “Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature,” Endocrine Pathology, vol. 23, no. 2, pp. 115–122, 2012.